

Chem-E8135 Microfluidics and BioMEMS

24.3.2021

Tarja Nevanen, VTT
Principal Scientist, Biosensors team

tarja.nevanen@vtt.fi

24/03/2021 VTT – beyond the obvious

Definition of BioMEMS

BioMEMS:

Biological or Biomedical Micro-Electro-Mechanical Systems
Also devices without electro-mechanical components, (DNA and protein arrays) are often categorized under BioMEMS

Bashir 2004: "devices or systems that are used for processing, delivery, manipulation, analysis, or construction of biological and chemical entities

Lab-on-a-chip (LOC) and micro-total analysis systems (μ TAS):
bioanalytical systems scaled down and integrated onto a single chip.

Dimensions

MEMS devices have dimensions ranging from 100 nm to 1 mm

Diameter of DNA alpha helix: 2 nm

Proteins: 1- tens of nanometers scale

Viruses: 30-100 nm scale

Bacteria: 0.2-10 μm

Mammalian cells: 10-30 μm

BioMEMS applications

MEMS sensors for the biological systems, no biocomponent included

- Pressure sensors e.g. blood or intraocular pressure sensors
- Inertial sensors e.g. defibrillators, pacemakers
- Hearing-aid transducer

MEMS sensors having a functional biocomponent

- Diagnostic and analytical devices
- Medical applications
- Tools for research

Driving forces towards BioMEMS 1.

Diagnostics

Demand for higher-quality medical care:

Point-of-care testing, home testing (COVID-19 case!)

Preventive care

Personalized medicine

Continuous monitoring

Solutions needed for "Medical care to all"


Simple, user-friendly (easy-to-use)

Minimally invasive procedures

Low-cost

Minimal sample and waste

No contamination



Jung 2015 Fig. 1. Schematic illustration showing a desired POCT diagnostic system having the "sample-to-answer" capability.

Other diagnostic/ analytical application fields: Industry, food safety and quality, environment)

Why microsystems for diagnostics?

A typical microfluidic system moves, mixes and controls small volumes of fluids (nanolitres)

components include: needles, channels, pumps, mixers, valves, sensors, filters, dispensers, reservoirs

A typical point-of-care diagnostic microfluidic system handles biofluids as a sample. Device performs sampling, sample preparation, analyte detection, signal amplification (data analysis and results display)

Microscale diagnostic systems enable:

Miniaturization

Lower reagent, sample and power consumption

Faster analysis

Portable, no cross-contamination with disposable μ -devices

Automation

higher throughput

controlled/closed devices: decreased risk of contamination of the end user

better control of assay parameters

reduces needs for highly skilled personnel as end users

Integration (the main challenge at the moment)

sampling, sample preparation, analysis, detection, data transmission

multiplexed analysis

Driving forces towards BioMEMS 2.

Medical applications


Examples of commercial products (according to the survey of Yole Developpement)

Kidney dialysis monitoring (pressure sensors)

Hearing aids (silicon microphones, microelectrodes)

Smart pills for intestinal imaging

Microneedles for transdermal drug delivery



Du et al 2019, Yu et al 2015

A major challenge: integration of diagnostic devices with therapeutic devices
implantable devices (passive / **responsive**)

BioMEMS tools for drug development (Tiina Sikanen 10.3.2021):

Automated, multiplexed, high-throughput screens for drug candidate libraries

Cells, organs, multiorgans –on-a-chip

Driving forces towards BioMEMS 3.


Research tools

For different omics

Genomics, peptidomics,
transcriptomics, proteomic,
glycomics, lipidomics etc.

High-throughput studies possible
e.g. normal versus cancer cells

Evolution-on-a-chip
e.g. antibiotic resistance



Driving forces towards BioMEMS 4.

Novel / recent possibilities

Single cell analysis / function in a real time

Measurements of mRNA, protein, chemical profiles, oxygen, pH

Whole genome sequencing

Also as a function of controlled stimulus

Understanding of basic cellular functions (e.g. apoptosis, differentiation,) and their implications on disease states (e.g. malignancy)

Novel biological findings: exosomes (extracellular vesicles produced by cells, intensive research ongoing around the functions of exosomes and their potential in e.g. diagnostics)

Driving forces towards BioMEMS 4.

Novel / recent possibilities

Single cell analysis / function in a real time (Päivi Saavalainen 3.3.2021)

Measurements of mRNA, protein, chemical profiles, oxygen, pH

Whole genome sequencing


Also as a function of controlled stimulus

Understanding of basic cellular functions (e.g. apoptosis, differentiation,) and their implications on disease states (e.g. malignacy)

Novel biological findings: exosomes

extracellular vesicles produced by cells,
intensive research ongoing around the
functions of exosomes and their potential in
Diagnostics and therapy

Kalluri and DeBlau, 2020



Specific features introduced to MEMS by biomolecules

BIOMOLECULES AND CELLS ARE SUBJECTED TO A NON-NATURAL ENVIRONMENT!

Bioapplications

Applications are miniaturized systems or they contain novel solutions

Properties of the samples and analytes vary a lot!
Nucleic acids, proteins, small molecules.
Clinical samples, food or environmental samples

Fabrication / construction approaches

Maintain the functionality of the biomolecules (dryness-, temperature-, pH-sensitive)
Preserve stability in biointerface (e.g. immobilization) and in packaging (e.g. during lidding)

Biocompatibility (interaction of the material with e.g. human body)

Concern for *in vivo* devices (experience from e.g. pace makers) and to some extent also wearables

Safety issues (toxins, microbes)

prevention of contamination / infection
material choices, costs, life cycle of the device, waste management

Nucleic acids in microsystems as components or target analytes

Nucleic acids

DNA versus RNA

DNA in procaryotes and eucaryotes

RNA in viruses (also DNA)

Genes and non-coding sequences

Notice the differences in stability between DNA and RNA, single versus double stranded

Location

Eukaryotes (humans, animals, plants): DNA is in nucleus (membrane-bounded intracellular compartment), tightly packed in chromosomes

Prokaryotes (e.g. bacteria): no compartment for DNA, additional small genetic elements: e.g. plasmids

Viruses: DNA/RNA packed inside the virus coat

Notice the location and packing mode of the genetic element when designing BioMEMS applications for nucleic acid detection, pay attention especially to the sample preparation requirements

DNA in BioMEMS

Self-complementarity is a unique feature!

Utilized in identification, immobilisation, construction, isolation, amplification

Convenient to handle (stable)


Many protocols and BioMEMS device constructions

Isolation, digestion, amplification, hybridization, detection

Compatible with many materials

Single stranded DNA/RNA may have unspecific interactions to surfaces/materials

The double-helix structure of DNA



Double strand (ds), single strand (ss)
Long and narrow molecule
Linear or circular by nature
3D molecule by engineering (aptamers)

**Single DNA strand recognizes
a complementary sequence
on another single strand of DNA=**
Hybridization


**Important in amplification (PCR)
and constructs (targetting, aptamers,
Origamis)**
Very specific!

Replication (important in PCR applications)

Semiconservative = both DNA strands act as a template for new DNA

Aim: identical copies

Amount of DNA: 2^n , n = cycles of replication



Parental strands

Alberts et al




Figure 5–28 A mammalian replication fork. The fork is drawn to emphasize its similarity to the bacterial replication fork depicted in Figure 5–27.

***In vivo*: natural conditions, many assisting proteins are included**

***In vitro* (PCR): non-natural conditions (temperature, buffer, thermostable polymerases primers)**

Primer: a small sequence of a single-stranded DNA. Attaches to the template DNA and initiates replication

BioMEMS example: DNA extraction - from whole blood

Whole blood contains red blood cells, white blood cells (many different types, sizes vary), platelets, plasma (proteins, lipids and small molecules)

DNA is in the nucleus of white blood cells.

One way to extract DNA from whole blood is to **trap the white blood cells by a microfilter** (while everything else flows through), then **lyze** (break down) **the white cells and extract DNA**



Fig. 6. Biological protocol steps for DNA purification silicon chip.




Fig. 4. The integrated DNA extraction chip, the dimension of the chip is $2\text{ cm} \times 2\text{ cm}$.




Fig. 7. Flow diagram for DNA extraction.

BioMEMS example: DNA analysis, sizing, separation

Determination of the size of DNA or DNA fragments cutted by restriction enzymes

Electrophoresis separates DNA fragments based on their size.

The nucleic acids are transported in a capillary or microfluidic channel by an electric field
Calibration ladder as a reference.

Commercially available (e.g. Agilent2100Bioanalyzer, LabChip GX (PerkinElmer))

Benefits: lower consumption (1 μ l sample and reagents)

high sensitivity (0.1 ng fragments)

reduced assay time (several samples in 30 min)

high degree of automation and data handling

Application potential:

-Research tool

search for positive clones, quality check for DNA (purity, uniformity)

-Forensic studies

Genetic fingerprinting: highly variable repeating sequences,
identification of human remains, paternity testing etc



Agilent DNA chip

BioMEMS example: Genome analysis of a single cell (Marcy et al 2007)

Amplification of a genome of a single cell

Motivation:

Not all interesting and relevant micro-organisms can be cultivated

Need for analysis of the genome of individual cells isolated from e.g. soil, geysirs

Multiple Displacement Amplification (MDA)


60 nl reactions, 10^7 copies of the genome

Compared to standard 50 μ l amplification reaction

Benefits:

Less non –specific DNA synthesis and amplification bias (these are drawbacks of MDA in standard scale)


High quality material to the sequencing of the genomic DNA



BioMEMS example: DNA as a construction material

- Examples in nanoscale studies/demonstrations
- DNA hybridization makes possible to design 2-3D structures from DNA and also to functionalize the constructs
- **DNA origames**
 - Biosensing, enzyme cascades
 - drug delivery
- **Aptamers**

Structure of an Aptamer



Example structure
of an aptamer
against Vitamin B₁₂

Naturally folds into a unique structure with
high affinity and specificity to its target

www.technologyinscience.blogspot.com





Figure 1. AFM images of different AuNP assemblies on mica: (A) four corners, (B) a pair of parallel bars, (C) ring, and (D) H shape. The patterns are programmed by extending different staples with the same complementary sequence, permitting the use of the same AuNP–DNA conjugates for all assemblies. All scale bars are 250 nm. The size of the particles appears enlarged, due to convolution with the AFM tip. Schematic on the right shows the designed structures.

Structure of an Aptamer




Potential use in diagnostic platforms as a recognition element in sensors

- Single stranded DNA, isolated from a library of synthetic oligonucleotides
 - Affinity (μM to pM) and specificity towards a target molecule
- High stability (DNA), small size (proximity to sensor surface, low unspecific binding), easy and reproducible synthesis *in vitro*, simple to modify, suitable for different detection modes (optical, electrochemical etc)

Recent review Marrazza (2017) <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5371778/>

Proteins in microsystems as components or target analytes



Proteins have a huge structural variability!

Examples of different sizes and shapes of proteins

Variables: size, shape, surface charge, stability, aggregation tendency


Proteins have different interactions and functionality (binding, catalysis, structural component)

In vivo most of the cellular proteins are in contact with other proteins = protein complexes

Stability

IMPORTANT: In BioMEMS systems the proteins are not in their natural environment.

Disturbances have effect on the stability and functionality of the proteins



Conformation of lowest energy

Folding / refolding of proteins

In vivo: Folding starts during the synthesis of the polypeptide chain


chaperones = assisting proteins

Uncorrectly folded proteins are degraded or form aggregates

Important in BioMEMS when e.g. printed and dried proteins are used: is the protein able to refold by itself and in which conditions?

E.g. for the binding capacity of the sensing surface of the BioMEMS device it is important that all binding proteins are functional. Unfunctional binding proteins cause decrease in sensitivity.

In case of reusable or continuously used BioMEMS devices the functionality of the binding proteins need to be ensured



Balchin et al. 2020



Microfluidics/BioMEMS for proteins

Proteins as targets (single or multiple proteins or proteome)

Proteins as tools (capture or detection molecules)

Antibodies are the most widely used binding molecules for capture and detection

Small antibody fragments (Fab, scFv, nanobody) bring advantages to BioMEMS



Antibodies as an example of widely used proteins in microsystems

Introduction to antibodies

**Produced by mammalian immune system (B-lymphocytes),
protection against invaders**

e.g. viruses, foreign proteins, bacteria

**Enormous potential to recognize a wide variety
of molecules (diversity)**

Antibody gene libraries (size $>10^8$ clones)

High specificity of the recognition

low molecular weight compounds, peptides, proteins,
oligosaccharides, cells, viruses, inorganic materials/surfaces




High affinity binding

equilibrium reaction
association – dissociation phases
fM affinities by mutagenesis, $<nM$ from immunizations

Antigen= substance that can induce antibody production *in vivo*
(infection/immunisation)

Hapten= small compound which in itself cannot elicit the immune response
but as a protein conjugate becomes immunogenic.

$\sim 10^8$
ANTIBODY
PHAGES



T. Parkkinen, UEF

Recombinant antibodies (only the antigen binding domains, gene available, produced in microbes)

Microsystems introduce a non- natural environment for antibodies! Materials, liquid composition (buffer versus e.g. serum), supporting molecules are missing, temperature

Protein engineering makes possible to improve the properties of the recombinant antibodies for BioMEMS

Conserved structure

lots of structural and sequence data = knowledge-based approach

in vitro evolution techniques

mutant libraries, selection in harsh conditions and screening

Affinity and specificity

association-dissociation behaviour makes the difference

fM affinities by mutagenesis (corresponds to biotin-avidin interaction)

Stability

extended half-life, stability in various conditions, resistance to surface denaturation or dry atmosphere VTT

also non-engineering options (e.g. chemical cross- linking)

Labeling


additional and designed sites for labels

Immobilisation


oriented, site-directed,

single residues (Cys for gold), aminoacid tags (e.g. histidines), binding domains

Improved labelling



Oriented immobilization



VTT

Examples of antibodies in BioMEMS

Soluble assay format: measuring the concentration of the analyte (here MMP-8, biomarker for inflammation of gums)







Fig. 1. μ CEI device layout. Fluid wells are labeled according to contents as follows: S, sample; B, buffer; SW, sample waste; BW, buffer waste; mAb*, fluorescently labeled monoclonal antibody to MMP-8. Polyacrylamide gel composition is indicated by grayscale shading (%T and %C are percentage of total acrylamide and bis-acrylamide cross-linker, respectively). Inset shows a 40 \times bright-field image of the size-exclusion membrane. (Scale bar, 100 μ m.)






Antibodies in BioMEMS, soluble assay example 2



Two analytes detected simultaneously
350 μ m separation channel needed
Quantitative assay completion in <10 s
LODs: CRP 11ng/ml, TNF α 40ng/ml

Antibodies in BioMEMS

Point-of-care test for TSH (thyroid stimulating hormone)




Compared to ELISA:

Faster, less interventions
Lower reagent consumption
Comparable sensitivity

Antibodies in BioMEMS

Diagnostics: Self-powered integrated microfluidic blood analysis system (SIMBAS)



- Integrated blood plasma separation and multiplexed assays
- 5 μ l of whole blood
- Self priming degassing-driven flow technique (generated when device is removed from its vacuum packing)
- An example:
 - Pattern of 15 μ m bars of avidin, spiked blood with fluorescently labelled biotin
 - Picomolar detection concentrations achieved

Details next slide

Diagnostics: Self-powered integrated microfluidic blood analysis system (SIMBAS)





Fig. 2 Degas-driven flow is generated when the SIMBAS device is removed from a low-pressure environment. (A) Fast and effective plasma separation of 5 separate whole-blood samples by (B) filter trench (cylindrical cavity) and gravity-driven blood cell sedimentation generates blood-cell-free plasma in the self-priming untethered SIMBAS, see ESI† Movie SF1. (C) Plasma fills the suction chamber.

The lid can be removed and bound analytes further analysed (PCR/MS)

References used for figures

Alberts et al. *Molecular biology of the cell*

Balchin et al. (2020) *FEBS letters* 594: 2770-2781

Dimov (2011) *Lab chip* 11:845-850

Du et al. (2019) *ACS Appl Mater Interfaces* 11: 43588-43598

Herr (2007) *PNAS* 104: 5268-5273

Hou C (2010) *Anal Chem.*82: 3343-

Ji et al. (2007) *Sensors and actuators A*, 139: 139-144

Jung et al. (2013) *Lab Chip* 13: 4653-

Jung et al. (2015) *Microelectronic Engineering* 132 (2015) 46-57

Kalluri and LeBleu (2020) *Science* 367, 640

Marcy et al. (2007) *PLOS Genet.* 3 (9): e155

Marrazza (2017) *Biosensors* 7: 5-

Pilo-Pais et al. (2011) *Nano Lett* 11: 3489-3492

Pray (2008) *Nature Education* 1(1):100

Yu et al. (2015) *PNAS* 112: 8260-8265

bey⁰nd

the obvious

First Name Surname
firstname.surname@vtt.fi
+358 1234 5678

@VTTFinland
@your_account

www.vtt.fi